Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3034% below fair value
$25.57+1.34 (+5.53%)
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Veracyte pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Veracyte's pe ratio was 17.9× on Nov 11, 2026, against 124.6× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 17.9× | −92.9 |
| 2025 | Dec 31, 2025 | 110.8× | – |
See a number that looks wrong?